Inhibition of ovulation by intranasal nafarelin, a new superactive agonist of GnRH
Gudmundsson, J.A.; Nillius, S.J.; Bergquist, C.
Contraception 30(2): 107-114
1984
ISSN/ISBN: 0010-7824 PMID: 6238805 DOI: 10.1016/0010-7824(84)90094-5Document Number: 562824
30 healthy female volunteers used a new superactive stimulatory anaog of the hypothalamic gonadotropin-releasing hormone (GnRH) for inhibition of ovulation and contraception over a 3 month period. The potent GnRH agonist nafarelin (D-Nal(2)6GnRH) was administered intranasally in a daily dose of 125 mcg to 15 women and 250 mcg to 15 women. The treatment inhibited ovulation in all women during the 89 months of therapy. No pregnancies occurred during 59 treatment months in which no additional contraceptives were used. The mean estradiol concentration decreased during the 3 months treatment within the normal range for the early to midfollicular phase of the menstrual cycle. Results suggest that the GnRH agonist nafarelin has potential for contraception because of its inhibition of ovulation in women.